Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial
…, EE de Lange, AL Weltman, NL Shah, AM Al-Osaimi… - Journal of …, 2015 - Elsevier
Background & Aims This study’s aim was to assess the histological and metabolic effects of
n-3 polyunsaturated fatty acids (PUFAs) vs. placebo while adjusting for the impact of age and …
n-3 polyunsaturated fatty acids (PUFAs) vs. placebo while adjusting for the impact of age and …
Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam
…, UC Turba, WEA Saad, AW Park, AM Al-Osaimi… - Journal of Vascular and …, 2011 - Elsevier
PURPOSE: Balloon-occluded retrograde transvenous obliteration (BRTO) of bleeding
gastric varices (GV) is well described in the literature. Using Ethanolamine oleate as the …
gastric varices (GV) is well described in the literature. Using Ethanolamine oleate as the …
Accelerated treatment using intensity‐modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma
A McIntosh, KD Hagspiel, AM Al‐Osaimi… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: Patients with unresectable hepatocellular carcinoma (HCC) have limited
treatment options. In this study, the authors investigated the feasibility, toxicity, and efficacy …
treatment options. In this study, the authors investigated the feasibility, toxicity, and efficacy …
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
CK Argo, PG Northup, AMS Al-Osaimi, SH Caldwell - Journal of hepatology, 2009 - Elsevier
BACKGROUND/AIMS: Non-alcoholic steatohepatitis (NASH) is a growing public health
problem. Evaluation of risk factors for fibrosis in NASH will help to target resources to reduce …
problem. Evaluation of risk factors for fibrosis in NASH will help to target resources to reduce …
Obesity and hepatocellular carcinoma
SH Caldwell, DM Crespo, HS Kang, AMS Al-Osaimi - Gastroenterology, 2004 - Elsevier
Epidemiological studies have shown that obesity is a risk factor for hepatocellular carcinoma.
Similar studies further indicate that diabetes is also a major risk factor. Both obesity and …
Similar studies further indicate that diabetes is also a major risk factor. Both obesity and …
Therapy of NAFLD: antioxidants and cytoprotective agents
CY Chang, CK Argo, AMS Al-Osaimi… - Journal of Clinical …, 2006 - journals.lww.com
Lipid peroxidation and secondary cellular injury are the dominant mechanism in the
transition from relatively stable hepatic steatosis to potentially progressive steatohepatitis in …
transition from relatively stable hepatic steatosis to potentially progressive steatohepatitis in …
Hepatocellular ballooning in NASH
…, T Wilkinson, P Toms, CK Argo, AMS Al-Osaimi… - Journal of …, 2010 - Elsevier
BACKGROUND & AIMS: Hepatocellular ballooning is a key finding in nonalcoholic steatohepatitis
(NASH). It is conventionally defined by hemotoxylin and eosin (H&E) staining showing …
(NASH). It is conventionally defined by hemotoxylin and eosin (H&E) staining showing …
Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center US analysis
NJ Procaccini, AMS Al-Osaimi, P Northup… - Gastrointestinal …, 2009 - Elsevier
BACKGROUND AND OBJECTIVES: Gastric variceal hemorrhage treatment remains a difficult
issue for clinicians. There is controversy regarding whether first-line treatment should be …
issue for clinicians. There is controversy regarding whether first-line treatment should be …
NASH and cryptogenic cirrhosis: a histological analysis
…, VD Lee, DE Kleiner, AMS Al-Osaimi… - Annals of …, 2009 - medigraphic.com
Introduction: Epidemiological studies indicate that nonalcoholic steatohepatitis (NASH) is a
common cause of cirrhosis described as ‘cryptogenic’. To address this from a histological …
common cause of cirrhosis described as ‘cryptogenic’. To address this from a histological …
[PDF][PDF] A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation
…, S Saab, ML Shiffman, AMS Al‐Osaimi… - …, 2013 - Wiley Online Library
Hepatitis C virus (HCV) infection recurs in liver recipients who are viremic at transplantation.
We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant …
We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant …